Allergan gains approval for macular oedema treatment

Allergan gains approval for macular oedema treatment

By Adrian Galbreth

Allergan has announced that the European Medicines Agency has granted marketing authorisation for its Ozurdex drug.

The medication is the first licensed treatment in Europe for macular oedema in patients with retinal vein occlusion, which is the second most common retinal vascular disease after diabetic retinopathy and is a key cause of vision loss.

David Endicott, president of Allergan for Europe, the Middle East and Africa, said he is "delighted" that the drug has been approved.

"As a leading company in ophthalmology, Allergan are pleased to enter the retina market and to provide physicians and their patients with the first European-licensed drug treatment for macular oedema following retinal vein occlusion," he said.

Recently, a team of researchers from Finland found that sea buckthorn oil could ease the symptoms of the common condition dry eye syndrome, as it reduced the increase in tear film osmolarity and, therefore, positively affects the symptoms.

by Adrian Galbreth

« Back to list